Bristol Baraclude Will Be Available April 8; Premium Price Planned
Executive Summary
Bristol-Myers Squibb's Baraclude (entecavir) will be available on pharmacy shelves April 8 following FDA approval of the hepatitis B therapy
You may also be interested in...
Bristol Late-Stage Pipeline Reflects Success Of In-House Development
Bristol-Myers Squibb's late-stage pipeline will include 80% internally developed agents, with three of those compounds moving into Phase III
Bristol Late-Stage Pipeline Reflects Success Of In-House Development
Bristol-Myers Squibb's late-stage pipeline will include 80% internally developed agents, with three of those compounds moving into Phase III
Pegasys Adds Hepatitis B Indication, But Not Superiority Claim Over Epivir
Roche is highlighting Pegasys' limited duration of treatment relative to other hepatitis B therapies following approval of the supplemental indication